RxDoctor Payments Data

Christopher Doig, DO

Internal Medicine · Garden City, MINPI 1942258199

Payments from drug & device makers

$905in general payments, 2019–2025

Across 53 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$226
  • Johnson & Johnson$215
  • GSK$127
  • AbbVie$59
  • Exact Sciences$41
  • Sumitomo Pharma America, Inc.$32
  • plus $205 from 11 others

What the payments were for

  • Food & beverage$89699%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$905 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$158,199
Medicare patients
298
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$86,728
JardianceEmpagliflozin53$57,623
OzempicSemaglutide35$54,085
JanuviaSitagliptin Phosphate33$50,819
TrulicityDulaglutide46$50,471
TradjentaLinagliptin44$27,165
XareltoRivaroxaban31$25,569
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,251
EntrestoSacubitril/Valsartan18$17,011
FarxigaDapagliflozin Propanediol16$12,186
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$6,814
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$5,492
Atorvastatin Calcium377$4,949
Omeprazole129$2,308
Levothyroxine Sodium166$2,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$226$86,72894 claims
Novo NordiskOzempic$29$54,08535 claims
Lilly USA, LLCTrulicity$14$50,47146 claims
Johnson & JohnsonXarelto$215$25,56931 claims
GSKTrelegy Ellipta$127$17,25118 claims
NovartisEntresto$19$17,01118 claims
AbbVieSynthroid$59$2,14317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Garden City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →